Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

The Top 5 Biosimilar Articles for the Week of February 3

February 7th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of February 3, 2025.

CHMP Pushes 3 Biosimilars Forward, Spelling Hope for Ophthalmology, Supportive Care Markets

February 6th 2025

By Skylar Jeremias

Article

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European approval and expanding patient access.

Interchangeable Aflibercept Biosimilar, Enzeevu, Comparable With Eylea for nAMD

February 6th 2025

By Cameron Santoro

Article

Enzeevu (aflibercept-abzv), a biosimilar developed by Sandoz, demonstrated biosimilarity to reference aflibercept (Eylea) in patients with neovascular age-related macular degeneration (nAMD).

The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars

February 5th 2025

By Skylar Jeremias

Article

Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.

The Banking of Biosimilars: Insights From a Leading Health Economist

February 4th 2025

By Skylar Jeremias

Article

Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.

BioRationality: No More Biosimilars—Just Biogenerics

February 3rd 2025

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, recognizing them as "biogenerics" since physicochemical and in vitro biological comparisons are sufficient to ensure safety and efficacy.

Understanding Biosimilars Through Education and PBM Formulary Perspective

February 2nd 2025

By Cameron Santoro

Video

Josh Canavan, PharmD, head of pharmacy at RazorMetrics, recommends key educational resources for biosimilars, and emphasizes the extensive research conducted before pharmacy benefit managers (PBMs) add medications, including biosimilars, to their formularies.

Biosimilars Rheumatology Roundup: January 2025

February 1st 2025

By Skylar Jeremias

Article

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, and the FDA approval of the third tocilizumab biosimilar.

Welcome Wezlana: The First Stelara Biosimilar to Launch in the US

January 31st 2025

By Skylar Jeremias

Article

January 1 marks the launch of the first biosimilar referencing Stelara (ustekinumab) in the US, ushering in a new class of lower-cost medicines for patients with rheumatic and gastrointestinal conditions.

FDA Approves Celltrion's Avtozma as Third Tocilizumab Biosimilar

January 31st 2025

By Skylar Jeremias

Article

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions. It is the third biosimilar to reference Actemra (tocilizumab) to be approved for US patients.